Ambeed.cn

首页 / / / JAK / Ivarmacitinib

Ivarmacitinib {[allProObj[0].p_purity_real_show]}

货号:A1443404 同义名: SHR0302 Ambeed 开学季,买赠积分,赢豪礼

Ivarmacitinib (SHR0302)是一种有效的、口服活性的 JAK 抑制剂,特别对 JAK1 的选择性高于 JAK2 10 倍,JAK3 77 倍,Tyk2 420 倍。它能够抑制 JAK1-STAT3 磷酸化并诱导肝星状细胞的凋亡,具有抗增殖和抗炎作用。

Ivarmacitinib 化学结构 CAS号:1445987-21-2
Ivarmacitinib 化学结构
CAS号:1445987-21-2
Ivarmacitinib 3D分子结构
CAS号:1445987-21-2
Ivarmacitinib 化学结构 CAS号:1445987-21-2
Ivarmacitinib 3D分子结构 CAS号:1445987-21-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Ivarmacitinib 纯度/质量文件 产品仅供科研

货号:A1443404 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 JAK1 JAK2 JAK3 Tyk2 其他靶点 纯度
Decernotinib +++

JAK1, IC50: 11 nM

JAK1, Ki: 11 nM

+++

JAK2, Ki: 13 nM

++++

JAK3, Ki: 2.5 nM

+++

TYK2, Ki: 13 nM

{[allProObj[0].p_purity_real_show]}
ZM39923 HCl +

JAK1, pIC50: 4.4

+

JAK3, pIC50: 7.1

EGFR {[allProObj[0].p_purity_real_show]}
Cerdulatinib +++

JAK1, IC50: 12 nM

+++

JAK2, IC50: 6 nM

+++

JAK3, IC50: 8 nM

++++

TYK2, IC50: 0.5 nM

{[allProObj[0].p_purity_real_show]}
Momelotinib +++

JAK1, IC50: 11 nM

++

JAK2, IC50: 18 nM

+

JAK3, IC50: 155 nM

{[allProObj[0].p_purity_real_show]}
XL019 +

JAK1, IC50: 134.3 nM

++++

JAK2, IC50: 2.2 nM

+

JAK3, IC50: 214.2 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Ruxolitinib +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

{[allProObj[0].p_purity_real_show]}
Tofacitinib +

JAK1, IC50: 112 nM

++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

{[allProObj[0].p_purity_real_show]}
Ruxolitinib (S enantiomer) +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

++

TYK2, IC50: 19 nM

{[allProObj[0].p_purity_real_show]}
Filgotinib +++

JAK1, IC50: 10 nM

++

JAK2, IC50: 28 nM

+

JAK3, IC50: 810 nM

+

TYK2, IC50: 116 nM

{[allProObj[0].p_purity_real_show]}
Baricitinib +++

JAK1, IC50: 5.9 nM

+++

JAK2, IC50: 5.7 nM

++

TYK2, IC50: 53 nM

{[allProObj[0].p_purity_real_show]}
Gandotinib ++

JAK1, IC50: 19.8 nM

++++

JAK2, IC50: 0.288 nM

JAK2 (V617F), Ki: 0.245 nM

++

JAK3, IC50: 48.0 nM

++

TYK2, IC50: 44 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Oclacitinib maleate +++

JAK1, IC50: 10nM

++

JAK2, IC50: 18nM

+

JAK3, IC50: 99nM

+

TYK2, IC50: 84nM

{[allProObj[0].p_purity_real_show]}
NVP-BSK805 2HCl ++

JAK1, IC50: 31.63 nM

++++

JAK2, IC50: ~0.5 nM

++

JAK3, IC50: 18.68 nM

+++

TYK2, IC50: 10.76 nM

{[allProObj[0].p_purity_real_show]}
Peficitinib {[allProObj[0].p_purity_real_show]}
Go6976 FLT3 {[allProObj[0].p_purity_real_show]}
AZD-1480 ++++

JAK2, IC50: 0.26 nM

{[allProObj[0].p_purity_real_show]}
Fedratinib +++

JAK2, IC50: 3 nM

JAK2 (V617F), IC50: 3 nM

RET,FLT3 {[allProObj[0].p_purity_real_show]}
WP1066 +

JAK2, IC50: 2.3 μM

{[allProObj[0].p_purity_real_show]}
Curcumol {[allProObj[0].p_purity_real_show]}
AZ960 ++++

JAK2, IC50: <3 nM

JAK2, Ki: 0.45 nM

{[allProObj[0].p_purity_real_show]}
GLPG0634 analog {[allProObj[0].p_purity_real_show]}
CEP-33779 ++++

JAK2, IC50: 1.8 nM

{[allProObj[0].p_purity_real_show]}
FLLL32 +

JAK2, IC50: <5 μM

{[allProObj[0].p_purity_real_show]}
WHI-P154 +

JAK3, IC50: 1.8 μM

Src,VEGFR,EGFR {[allProObj[0].p_purity_real_show]}
BMS-911543 ++++

JAK2, IC50: 1.1 nM

+

JAK3, IC50: 75 nM

++

TYK2, IC50: 66 nM

{[allProObj[0].p_purity_real_show]}
TG101209 +++

JAK2, IC50: 6 nM

+

JAK3, IC50: 169 nM

RET,FLT3 {[allProObj[0].p_purity_real_show]}
AT9283 ++++

JAK2, IC50: 1.2 nM

++++

JAK3, IC50: 1.1 nM

{[allProObj[0].p_purity_real_show]}
Pacritinib ++

JAK2, IC50: 23 nM

JAK2 (V617F), IC50: 19 nM

+

JAK3, IC50: 520 nM

++

TYK2, IC50: 50 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Tofacitinib citrate ++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

{[allProObj[0].p_purity_real_show]}
FM-381 ++++

JAK3, IC50: 127 pM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Ivarmacitinib 生物活性

描述 The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway and involved in many crucial biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation[1].SHR0302 could inhibit the activation of T cells and modulate the differentiation of helper T (Th) cells by reducing Th1 and increasing regulatory T (Treg) cells. In addition, SHR0302 decreased the expression of chemokine receptor CXCR3 on donor T cells and the secretion of cytokines or chemokines including interleukin (IL)-6, interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), CXCL10, etc. thereby destroying the IFN-γ/CXCR3/CXCL10 axis which promotes the progression of GVHD. Besides, SHR0302 decreased the phosphorylation of JAK and its downstream STATs, AKT and ERK1/2, which ultimately regulated the activation, proliferation, and differentiation of lymphocytes[2]. SHR0302 suppressed the severity of AA rats by attenuating the arthritis index, arthritis global assessment and paw swelling degree, and alleviated histopathology of spleen and joint of AA rats. SHR0302 can inhibit the proliferation of T, B and FLS, and down-regulated cytokines TNF-α, IL-1β, IL-17 and antibody IgG1, IgG2a levels, and suppressed the proportion of Th17 and total B, and inhibited JAK1-STAT3 phosphorylation[3].

Ivarmacitinib 参考文献

[1]Ping Xin, Xiaoyun Xu,et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020 Mar;80:106210.

[2]Xi Sun,Qiaomei He,et al. Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease. Cell Transplant.Jan-Dec 2021;30:9636897211033778.

[3] Huaxun Wu, Shangxue Yan,et al. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 2016 Oct;83(5):525-32.

Ivarmacitinib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.06mL

2.41mL

1.21mL

24.13mL

4.83mL

2.41mL

Ivarmacitinib 技术信息

CAS号1445987-21-2
分子式C18H22N8O2S
分子量 414.48
别名 SHR0302
运输蓝冰
存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 30 mg/mL(72.38 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。